159 related articles for article (PubMed ID: 28905188)
1. Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity.
Lee HJ; Kim BK; Yoon KB; Kim YC; Han SY
Invest New Drugs; 2017 Dec; 35(6):733-741. PubMed ID: 28905188
[TBL] [Abstract][Full Text] [Related]
2. Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
Rüger N; Roatsch M; Emmrich T; Franz H; Schüle R; Jung M; Link A
ChemMedChem; 2015 Nov; 10(11):1875-83. PubMed ID: 26337137
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of PKF118-310 as a KDM4A inhibitor.
Franci G; Sarno F; Nebbioso A; Altucci L
Epigenetics; 2017 Mar; 12(3):198-205. PubMed ID: 27767379
[TBL] [Abstract][Full Text] [Related]
4. 4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
Morera L; Roatsch M; Fürst MC; Hoffmann I; Senger J; Hau M; Franz H; Schüle R; Heinrich MR; Jung M
ChemMedChem; 2016 Sep; 11(18):2063-83. PubMed ID: 27505861
[TBL] [Abstract][Full Text] [Related]
5. Benzo[
Kim YJ; Lee DH; Choi YS; Jeong JH; Kwon SH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775247
[TBL] [Abstract][Full Text] [Related]
6. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
Fang Z; Liu Y; Zhang R; Chen Q; Wang T; Yang W; Fan Y; Yu C; Xiang R; Yang S
Eur J Med Chem; 2021 Nov; 223():113662. PubMed ID: 34237635
[TBL] [Abstract][Full Text] [Related]
8. The role of the histone demethylase KDM4A in cancer.
Guerra-Calderas L; González-Barrios R; Herrera LA; Cantú de León D; Soto-Reyes E
Cancer Genet; 2015 May; 208(5):215-24. PubMed ID: 25633974
[TBL] [Abstract][Full Text] [Related]
9. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
Chu CH; Wang LY; Hsu KC; Chen CC; Cheng HH; Wang SM; Wu CM; Chen TJ; Li LT; Liu R; Hung CL; Yang JM; Kung HJ; Wang WC
J Med Chem; 2014 Jul; 57(14):5975-85. PubMed ID: 24971742
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity studies of a macrocyclic peptide inhibitor of histone lysine demethylase 4A.
Passioura T; Bhushan B; Tumber A; Kawamura A; Suga H
Bioorg Med Chem; 2018 Mar; 26(6):1225-1231. PubMed ID: 29402611
[TBL] [Abstract][Full Text] [Related]
11. Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy.
Cui SZ; Lei ZY; Guan TP; Fan LL; Li YQ; Geng XY; Fu DX; Jiang HW; Xu SH
Cancer Sci; 2020 May; 111(5):1567-1581. PubMed ID: 32133742
[TBL] [Abstract][Full Text] [Related]
12. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract][Full Text] [Related]
13. Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation.
Ding G; Xu X; Li D; Chen Y; Wang W; Ping D; Jia S; Cao L
Cell Death Dis; 2020 Oct; 11(10):893. PubMed ID: 33093461
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
Zhao B; Liang Q; Ren H; Zhang X; Wu Y; Zhang K; Ma LY; Zheng YC; Liu HM
Eur J Med Chem; 2020 Apr; 192():112161. PubMed ID: 32155529
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
16. Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.
Upadhyay AK; Judge RA; Li L; Pithawalla R; Simanis J; Bodelle PM; Marin VL; Henry RF; Petros AM; Sun C
Bioorg Med Chem Lett; 2018 Jun; 28(10):1708-1713. PubMed ID: 29691138
[TBL] [Abstract][Full Text] [Related]
17. Small molecule KDM4s inhibitors as anti-cancer agents.
Lin H; Li Q; Li Q; Zhu J; Gu K; Jiang X; Hu Q; Feng F; Qu W; Chen Y; Sun H
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):777-793. PubMed ID: 29651880
[TBL] [Abstract][Full Text] [Related]
18. Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells.
Xu X; Wang L; Hu L; Dirks WG; Zhao Y; Wei Z; Chen D; Li Z; Wang Z; Han Y; Wei L; Drexler HG; Hu Z
Int J Cancer; 2020 Jan; 146(2):400-412. PubMed ID: 31271662
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel Benzimidazole Pyrazolone Scaffold That Inhibits KDM4 Lysine Demethylases and Reduces Proliferation of Prostate Cancer Cells.
Carter DM; Specker E; Przygodda J; Neuenschwander M; von Kries JP; Heinemann U; Nazaré M; Gohlke U
SLAS Discov; 2017 Aug; 22(7):801-812. PubMed ID: 28346812
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2
Bhan A; Ansari KI; Chen MY; Jandial R
Cancer Res; 2021 Jun; 81(12):3200-3214. PubMed ID: 33941612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
